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Abstract
Model-based recursive partitioning (MOB) can be used to identify subgroups with differing treatment
effects. The detection rate of treatment-by-covariate interactions and the accuracy of identified subgroups
using MOB depend strongly on the sample size. Using data from multiple randomized controlled clinical
trials can overcome the problem of too small samples. However, naively pooling data from multiple trials
may result in the identification of spurious subgroups as differences in study design, subject selection and
other sources of between-trial heterogeneity are ignored. In order to account for between-trial heterogeneity
in individual participant data (IPD) meta-analysis random-effect models are frequently used. Commonly,
heterogeneity in the treatment effect is modelled using random effects whereas heterogeneity in the baseline
risks is modelled by either fixed effects or random effects. In this article, we propose metaMOB, a procedure
using the generalized mixed-effects model tree (GLMM tree) algorithm for subgroup identification in IPD
meta-analysis. Although the application of metaMOB is potentially wider, e.g. randomized experiments
with participants in social sciences or preclinical experiments in life sciences, we focus on randomized
controlled clinical trials. In a simulation study, metaMOB outperformed GLMM trees assuming a random
intercept only and model-based recursive partitioning (MOB), whose algorithm is the basis for GLMM
trees, with respect to the false discovery rates, accuracy of identified subgroups and accuracy of estimated
treatment effect. The most robust and therefore most promising method is metaMOB with fixed effects for
modelling the between-trial heterogeneity in the baseline risks.
Keywords model-based recursive partitioning · subgroup identification ·meta-analysis · IPD · treatment-by
subgroup interaction · personalized medicine
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1 Introduction
For precision medicine it is crucial to identify subgroups which benefit differently from a specific drug or
are exposed to particular harm. When subgroups are defined by single biomarkers or combinations of
biomarkers, different treatment effects in subgroups imply treatment-by-biomarker interactions. We use the
term biomarker here for not just genetic biomarkers, but also for other baseline patient characteristics as
e.g. demographic variables (Biomarkers Definitions Working Group, 2001). The biomarkers involved in
treatment-by-interactions are called predictive biomarkers, whereas prognostic markers predict the course
of a disease. Several statistical approaches for identifying subgroups with differential treatment effects were
proposed, e.g. review papers of Lipkovich et al. (2017) and Ondra et al. (2016). For subgroup identification
methods, specifically tree-based methods, one of the important factors influencing the performance is sample
size as has been shown in Sies and Van Mechelen (2017), Alemayehu et al. (2018) and Huber et al. (2019).
Data from one randomized controlled study are therefore often not sufficient for the identification of sub-
groups. The sample size can be increased by pooling data from multiple studies investigating the same
treatment or intervention. Although we consider randomized controlled trials here, the interest in identi-
fying interactions of biomarkers and interventions is potentially wider, e.g. randomized experiments with
participants in social sciences or preclinical experiments in life sciences. For instance, Patel et al. (2016)
developed a repository of individual-participant data (IPD) consisting of 19 randomized controlled trials in
order to investigate whether some patient populations suffering from low back pain benefit differently from
treatment. Cuijpers et al. (2007) conducted an IPD meta-analysis consisting of sixteen studies to investi-
gate the effect of active scheduling as behavioural treatment of depression. Analysing differential effects in
subgroups was also part of their research. Another example of an IPD is the International Weight Manage-
ment in Pregnancy (i-WIP) database. The i-WIP Collaborative Group collected data from 36 randomized
controlled trials in order to investigate the overall and differential effects of interventions based on diet and
physical activity during pregnancy, primarily on gestational weight gain and maternal and offspring com-
posite outcomes (The International Weight Management in Pregnancy (i-WIP) Collaborative Group, 2017).
Differences in the study designs, study populations, quality of the studies, choice of comparator intervention
or other study-specific influences can cause heterogeneity in baseline (control group) outcomes as well as in
treatment effect sizes from one study to another. We discuss these two (very different) types of heterogeneity
in turn. One approach to address the heterogeneity in the baseline is to use models with stratified intercepts
which estimates a separate intercept for each trial. Alternatively, the study intercepts can be considered
as random assuming a suitable distribution (e.g. normal). Whereas the approach with stratified intercept
does not have to make any assumptions regarding the distribution of intercepts across studies, a (paramet-
ric) random intercept approach needs fewer parameters to be estimated (Legha et al., 2018). Incorporating
between-study heterogeneity in the treatment effect into the modelling can be achieved by using random-
effect models. Various types of random-effect models have been suggested for aggregated meta-analysis.
Jackson et al. (2018) give an overview of random-effect models in meta-analysis for binary outcome data.
Between-study variations of the treatment effect are addressed by assuming the treatment effects to be nor-
mally distributed in all of the models presented by Jackson et al. (2018). Variations of the models arise due
to different assumptions regarding the heterogeneity in the baseline risks or the independence of the random
treatment and random baseline effects. In IPD meta-analysis models one-stage approaches using generalised
mixed effect models are increasingly used for the analysis (Simmonds et al., 2015). One-stage models do not
need to aggregate the IPD in a first step in order to analyse them with an appropriate meta-analysis models
in the second step. Legha et al. (2018) focus on different approaches regarding the baseline outcomes for
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modelling the between-trial heterogeneity in one-stage IPD meta-analysis models. Although, it is not the
main objective of Kontopantelis, one-stage models modelling the heterogeneity in the baseline differently are
also compared in Kontopantelis (2018).
For subgroup identification methods some approaches have been suggested in order to account for trial het-
erogeneity. However, these approaches are not sufficiently flexible and they use rather simplistic models
in order to account for between-trial heterogeneity. Subpopulation treatment effect pattern plot for meta-
analysis (Meta-STEPP) (Wang et al., 2016) for example is a method developed for investigating treatment
heterogeneity across one continuous covariate only. Meta- STEPP accounts for variations of the treatment
effect across trials by two different approaches: A fixed-effect (Wang et al., 2016) and a random effect (Wang
et al., 2018) meta-analysis approach. Nevertheless the investigation of multiple covariates at a time and
therefore, the detection of possible multi-way interactions with the treatment indicator are not possible in
this framework. For tree-based subgroup identification methods some approaches to account for between-
study heterogeneity are available. Accounting for between-study heterogeneity in tree-based methods is
crucial as ignoring heterogeneity can lead to the identification of spurious splitting variables and therefore
spurious subgroups as shown by Sela and Simonoff (2012). For SIDES (Lipkovich et al., 2011) and model-
based recursive partitioning (MOB)(Seibold et al., 2016; Zeileis et al., 2008) extensions have been proposed,
which adapt the algorithm by Sela and Simonoff (2012), allowing to account for heterogeneity, see Mistry
et al. (2018) and Fokkema et al. (2018), respectively. However, both investigate a simpler model assuming
heterogeneity in the baseline only. Systematic combinations of tree-based subgroup identification methods
and meta-analysis models which are adequately complex and flexible have not been investigated yet.
In this work, we introduce metaMOB which combines commonly made assumptions in meta-analysis models
with generalized linear mixed model-tree (GLMM-tree) algorithm by Fokkema et al. (2018). We investigate
metaMOB’s performance compared to the original MOB to the original MOB (Seibold et al., 2016; Zeileis
et al., 2008) and to the GLMM-tree investigated in Fokkema et al. (2018) in an extensive Monte-Carlo sim-
ulation study using an structured approach (Benda et al., 2010). Furthermore, we evaluate the impact of
using different assumptions on the baseline effect for metaMOB.
The remainder of this paper is organized as follows. In Section 2 we outline the subgroup identification
method MOB and its extension GLMM-trees. Moreover, we present different mixed-models appropriate
for IPD meta-analysis in Section 2.1. In Subsection 2.2 we introduce metaMOB. In the following section
we compare the performance of two variations of metaMOB to MOB and the GLMM-tree investigated by
Fokkema et al. (2018) in a simulation study. Finally, we discuss advantages and limitations of the investigated
methods in Section 4.
2 Methods
We consider IPD data from k = 1, . . .K randomized controlled trials investigating the same experimental
treatment against the same control on an outcome variable Y . For each patient i (i = 1, . . . , nk) of a trial k
the outcome yik, p baseline covariates denoted by xik1, . . . , xikp and the treatment group tik are observed.
The treatment variable T takes the value 1 for patients in the experimental treatment group and 0 for
patients in the control group.
Seibold et al. (2016) use the algorithm of MOB (Zeileis et al., 2008) for exploratory subgroup identifications.
MOB assumes that in presence of subgroups there is no single global model fitting the data well. Therefore,
MOB partitions the dataset with respect to some covariates in order to improve the model fit. For MOB a
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model for modelling the outcome has to be defined first. Using generalized linear models (GLM), we model
the expected outcome E(yik) of a patient given the treatment indicator tik through a linear predictor and a
suitable link function g() assuming that all observations are drawn from the same population.
E(yik|tik) = µik (1)
g(µik) = γ + θtik
Partitioning the data for improving the data fit in presence of subgroups leads to separate GLMs in each
obtained subgroup j (j = 1, . . . , J):
g(µikj) = γj + θjtik (M0)
Since we assume that the subgroup structure is not known, it is not possible to simply estimate the parameters
γj , the intercept term of subgroup j, and the treatment effect θj of subgroup j. MOB grows a tree in order
to find local models (see M0) which fit the data better.
MOB partitions the data when the model parameters of M0 are not stable over the considered covariates X.
The instability of the model parameters are assessed using the M-fluctuation by Zeileis and Hornik (2007) or
a permutation test when the assumption of normally distributed partial scores may not hold. More precisely
the MOB tree is obtained using the following algorithm:
1. Start with all observations included in the root node
2. Fit modelM0 to all observations in the given node by estimating the model parameters via minimizing
the objective function Ψ((Y,X), γ, θ) (e.g. the negative log-likelihood)
3. Asses parameter instabilities with respect to X1, . . . ,Xp by using the M-fluctuation test proposed by
Zeileis and Hornik (2007) or permutation test. The tested hypotheses are
Hγ,j0 : ψγ((Y,X, T ), γˆ, θˆ) ⊥ Xj , j = 1, . . . , p
Hθ,j0 : ψθ((Y,X, T ), γˆ, θˆ) ⊥ Xj , j = 1, . . . , p,
with ψγ and ψθ denoting the partial score functions of γ and θ, respectively.
4. If at least one of the 2 × p null hypotheses can be rejected at a pre-specified nominal level (using
Bonferroni multiplicity adjustment), select covariate Xj∗ with the lowest p-value as splitting variable.
5. Compute the split point for the chosen variable Xj∗ by optimizing the sum the objective functions of
the conceivable subsets.
6. Repeat Steps 2 to 5 until none of the hypotheses in Step 3 can be rejected or some other stopping
criteria (e.g. minimum number of observations in a node) is met.
Since MOB was developed to identify subgroups based on data from one single study, MOB ignores the
clustered structure of the data. Fokkema et al. (2018) proposed an algorithm extending MOB in order to
allow the assumption of heterogeneity between clusters. The extended algorithm called GLMM-trees uses
mixed models in order to model data from K studies. In contrast to GLMs (as used in MOB) assuming
independent and identically distributed observations, mixed models assume that observations between studies
are independent but observations within each study are correlated. The algorithm of GLMM-trees allows
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to detect treatment-by-subgroup interactions and non-linearities in generalized linear mixed-effect models
(GLMM). Fokkema et al. (2018) restricted their analyses to GLMMs with cluster-specific random intercepts
fitting the following model in each partition j:
g(µijk) = γj + θjtijk + b0k. (M1)
The centred random intercepts bk are normally distributed bk with expectation 0 and variance τ20 . GLMM-
trees using model M1 are referred to as MOB-RI in the following.
A random-intercept model allows only the baseline outcome to vary from study to study whereas the treat-
ment effects are assumed to be the same across studies. This assumption corresponds to a common-effect
meta-analysis model which is also known under the term fixed-effect meta-analysis model. The assumption of
estimating the same true treatment effect in every trial is a strong assumption (Jackson et al., 2018). There-
fore, the random-effects model is more plausible. Random-effects models for meta-analyses are outlined in
Subsection 2.1.
2.1 GLMMs for meta-analysis
Heterogeneous treatment effects are usually expected in meta-analysis. However, this assumption has not
been evaluated in the context of GLMM-trees so far. Several models for random-effect meta-analyses have
been suggested. Jackson et al. (2018) examined seven models for random-effect meta-analyses with binary
outcome using aggregated data. Legha et al. (2018) compare two approaches for one-stage IPD meta-analysis:
random-effect models with either random or stratified intercepts. These two approaches for modelling the
baseline are also considered in Jackson et al. (2018) and Kontopantelis (2018). The random-effects model
with stratified intercepts is defined as follows:
g(µik) = γk + θktik + ik (2)
with θk = θ + b1k
and b1k ∼ N (0, τ21 )
The baseline for trial k is denoted by γk and is assumed to fixed. The model parameter θk describes the
treatment effect in trial k which is assumed to be normally distributed with mean θ and a between-trial
variance τ21 .
The model for meta-analysis accounting for both heterogeneity in the treatment effect and in the baseline
by using random effects is defined in Equation 3.
g(µik) = γk + θktik + ik (3)
with γk = γ + b0k, θk = θ + b1k
and b0k ∼ N (0, τ20 ) and b1k ∼ N (0, τ21 )
The centered random effects b0k and b1k are assumed to be normally distributed. As in most models
considered in Jackson et al. (2018) we assume that the random effects b0 and b1 are independent.
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2.2 metaMOB
As for MOB, metaMOB assumes that in the presence of subgroups the parameters θ and γ of Equation 3
and 2 may not describe the data well. Therefore, the data is partitioned in J subgroups by using a tree
model. Using the model described in Equation 3 which is analogous to the Simmonds and Higgins’ model
with random study-specific effects (Jackson et al., 2018), we fit the following model to each subgroup j
identified by the algorithms described in Section 2.3:
g(µijk) = γj + b0k + θjti + b1kti, (M2)
where b1k ∼ N (0, τ21 ) and all b1k are independent. As for M1 we assume that the fixed effects γ and θ
are subgroup specific, also referred to as local parameters, whereas the random effect part is assumed to be
global, meaning that the random effects are the same across the identified subgroups.
The model fitted in each partition j assuming fixed baseline effects in each study is defined as:
g(µijk) = γjk + θjti + b1ktijk, (M3)
where the fixed-effects γjk and the mean treatment effect θj are assumed to be subgroup specific. For model
M3 the number of parameters to be estimated increases with an increasing number of identified subgroups
and increasing number of trials.
The method assumingM2 to be the underlying model for the tree growing procedure is called metaMOB-RI,
as a random intercept is assumed for the baseline effects. The tree growing procedure using the model with
a stratified intercept, M3, is referred to as metaMOB-SI in the following.
2.3 Algorithm
Models M0 to M3 can be represented by the model equation
g(µij) = x∗iT
(
γj
θj
)
+ zTi b, (4)
where b is a vector of random effects, vector zTi is the i-th row of the design matrix Z for the random effects,
vector x∗iT is the i-th row of the design matrix X for the fixed effects. The coefficient vector of the fixed
effects is denoted by(γj ,θj)T . For model M2 e.g. vector b of Equation 4 is b = (b01, . . . , b0K , b11, . . . , b1K)T .
Vector zi is a vector of length 2K, indicating to which study patient i belongs. Subject i enrolled in the
active treatment arm of study k has the value 1 at position k and K+ k. A subject i enrolled in the placebo
arm of study k is a unit vector with value one at position k. And vector x∗i of Equation 4 is of length 2K
with value 1 at position k and the value indicating the treatment patient i was assigned to at position K+k.
The vectors b, x∗i and zi depend on the chosen model (M0-M3) . The algorithm for MOB-RI, metaMOB-RI
and metaMOB-SI is outlined in the following.
1. Set r = 0 and all values bˆ(r) to 0.
2. Set r = r+ 1. Estimate a GLM tree using zTi bˆ(r−1) as an offset. The random effects part is treated as
offset because it is assumed to be equal across all subgroups and it is treated as known.
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3. Fit the chosen linear mixed effect models (model M1,M2 and M3) with terminal node j(r) from the
GLM tree estimated in the previous step.
Extract posterior predictions bˆ(r) from the estimated model.
4. Repeat (2) and (3) until the log-likelihood of the model in the previous steps converges. This is usually
the case, when the estimated tree does not change from previous iterations.
3 Simulation Study
In Section 2 we outlined four models used for the subgroup identifications procedure MOB, GLMM-tree
and metaMOB. Model M0 corresponds to a simple GLM ignoring the clustered structure of the data.
MOB as proposed by Seibold et al. (2016) aims at achieving a better model fit by fitting Model M0 to
each resulting partition. The tree-methods accounting for clustered data by assuming M1,M2 and M3 to
be the underlying models for the algorithm in Section 2.3 are referred to as MOB-RI, metaMOB-RI and
metaMOB-SI, respectively. In our simulation study using the Clinical Scenario Evaluation (CSE) framework
(Benda et al., 2010) we compared the performance of MOB, MOB-RI, metaMOB-RI and metaMOB-SI
in different IPD settings described in Section 3.1. CSE structures the simulation study into three parts,
namely assumptions, options and metrics. Dmitrienko and Pulkstenis (2017) use a different terminology
for the three components. The three components are named data models, analysis models and evaluation
models. Assumptions define the data generation process, options describe the methods applied to the data
and metrics specify the criteria for evaluating the methods applied to the data. The performance is assessed
by different measures presented in Section 3.3. The computational details and the chosen tuning parameters
for the algorithms are given in Section 3.2.
3.1 Assumptions: Simulation settings
Each dataset generated for our simulation study consists of a continuous response Y , a binary treatment
variable T and 15 covariates for each subject i = 1, . . . , nk of k = 1, . . . ,K trials. For simplicity, we assume
that each trial has the same number of observations n1 = . . . = nK . The total number of observations
is denoted by N . The treatment indicator T is either 0 or 1, each with a probability of 0.5. Adapted
from Dusseldorp et al. (2010) and Fokkema et al. (2018) the 15 covariates X1,. . . ,X15 are drawn from a
multivariate normal distribution with µX1 = 10, µX2 = 30, µX4 = −40 and µX5 = 70. The other means
are drawn from a discrete uniform distribution on the interval [−70, 70]. The variance of all Xp is set to
σ2Xp = 100. Furthermore, all 15 covariates are correlated with ρ = 0.3. The outcome Y is generated by
yik = f(xik, tik) + b0k + b1k ∗ tik + ik, with ik ∼ N(0, 52), b0k ∼ N(0, τ20 ) and b1k ∼ N(0, τ21 ). The values for
the varied parameters are presented in Table 1 . For each setting resulting from combining these parameters
2000 datasets are generated.
We investigated different data-generating models by varying the functional relationship of the outcome
and the covariates f(·) as defined in Table 2. The Null model is used for investigating the false discovery
rate. Sim A or Sim B are based on the tree structure in Figure 1 adapted from Dusseldorp et al. (2010) and
Fokkema et al. (2018).
The true data-generating model for settings with γj1 = . . . = γjK = µγj is either M0, M1 or M2
depending on the values of τ20 and τ21 . Drawing the overall mean for each study within a subgroup from
a normal distribution corresponds to M3 being the data generating model. Settings using Figure 1 with
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Parameter Values
Number of trials K 5, 10
Sample size N 200, 500, 1000
Heterogeneity in baseline τ0 0, 5, 10
Heterogeneity in treatment τ1 0, 2.5, 5, 10
Correlation between b0 or b1 and
one of the Xp variables
b0 (or b1) and all Xp uncorrelated, b0 (or b1) corre-
lated with one of the splitting variables (correlation
r ≈ 0.42), b0 (or b1) correlated with one of the non-
splitting variables (correlation r ≈ 0.42)
Table 1: Scenarios considered in the simulation study
Setting Functional relationship
Null model f(·) = 0
Sim A f(·) is given by the tree structure presented in Figure 1 with γj1 = . . . = γjK =
µγj , for j = 1, . . . , 4
Sim B f(·) is given by the tree structure presented in Figure 1 with intercepts
drawn from normal distributions: γ1k ∼ N(17.5, τγ), γ2k ∼ N(30, τγ),γ3k ∼
N(17.5, τγ), γ4k ∼ N(42.5, τγ) for k = 1, . . . ,K
Table 2: Functional relationship of the outcome and the covariates for the simulation study
equal intercept across studies within one subgroup are going to be referred to as Sim A and settings with
study-specific intercepts will be referred to as Sim B, respectively.
Furthermore, it has to be noted that for evaluating the false discovery rate using the Null model, all Xp are
non-splitting variables. Therefore, b0 or b1 are either uncorrelated with all of covariates, or correlated with
a non-splitting covariate.
3.2 Options: Methods and their tuning parameters
For the computation we used the software environment R (R Core Team, 2014). Version 1.2-3 of the R
package partykit(Hothorn and Zeileis, 2015) was used for growing MOB described in Section 2. For the
MOB-RI and the two variations of metaMOB we used Version 0.1-2 of the R package glmertree. Since
our simulations study focuses on a continuous outcome the functions used for the tree algorithms are called
lmtree for MOB and lmertree for MOB-RI and metaMOB. The stopping criteria were set to 5% level of
significance for the test in the splitting criterion and a minimum number of 20 observations in the terminal
nodes. Furthermore, we set the tolerance in the argument check.conv.grad of lme4 (Version 1.1-21) to a
five times higher value than the default. The glmertree package uses lme4 for step 3 of its algorithm
(see Section 2.3). The mixed models fitted for MOB-RI and metaMOB using lme4’s default value have a
poor convergence. Eager and Roy (2017) argue that convergence issues with the max|grad| tolerance arising
from the preset tolerance in the check.conv.grad argument is the least problematic of convergence errors.
Moreover, they state that in practice many researcher tend to ignore these convergence errors if no other
convergence issues are present. For metaMOB and MOB-RI we use REML estimation for fitting the linear
mixed effect models (Step 3 of the algorithm, see Section 2.3). The formulas used in the functions lmtree
or lmertree for the four algorithms are given below:
• MOB: y ∼ factor(trt) | x1+ ... +xp
• MOB-RI: y ∼ factor(trt) | trial| x1+ ... +xp
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X2
X1
γ2k+θ2T
with
µγ1=17.5
and
θ1=-5
γ2k+θ2T
with
µγ2=30
and θ2=0
X5
γ3k + θ3T
with
µγ3=30
and θ3=0
γ4k+θ4T
with
µγ4=42.5
and θ4=5
≤ 30
≤ 17 > 17
> 30
≤ 63 > 63
Figure 1: Data generating model adapted from Dusseldorp et al. (2010) and Fokkema et al. (2018) for
settings Sim A and Sim B.
• metaMOB-RI: y ∼ factor(trt) | (1|trial)+(trt-1|trial)| x1+ ... +xp
• metaMOB-SI: y ∼ factor(trial)+factor(trt) | (trt-1|trial)|| x1+ ... +xp
trt is the vector including the treatment indicator, trial is a vector indicating to which trial an observation
belongs and x1, ...+xp are the vectors of the p covariates considered as potential predictive markers.
3.3 Metrics: Performance criteria
The performance of the methods was assessed by different measures as false discovery rate, number of
identified subgroups, tree accuracy and the correlation of the true and estimated treatment effects in the
identified subgroups. Furthermore, we evaluate the computation time of the four algorithms and convergence
problems. These performance criteria are explained in more detail below.
The frequency of times the algorithm identified more than one final subgroup although none was present
is referred to as false discovery rate. The false discovery rate is also often referred to as Type I error rate,
although strictly speaking no test is performed. The null hypothesis, that no treatment-covariate interaction
is present, is rejected when a tree with at least one split is identified. The number of identified subgroups
corresponds to the number of terminal nodes. The tree accuracy takes the number of identified subgroups
into account and additionally evaluates the selection of the splitting covariate and the selected cut-off value.
A tree is considered to be accurate if the identified tree has the correct number of terminal nodes, all
splitting variables are selected correctly and when the selected cut-off values for the split denoted by c are
in the interval c± 5 with 5 corresponding to the population standard deviation.
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3.4 Results
3.4.1 Convergence and computation time
The GLMM-algorithm described in Section 2.3 is an iterative algorithms which stops when the difference
of the log-likelihood criterion of the corresponding mixed-effect model M1, M2 or M3 from two consecutive
iterations is below a threshold. This is the case when trees of subsequent iterations do not change. MOB-RI,
metaMOB-RI and metaMOB-SI always converged within 2 to 3 iterations steps within our simulation study.
As threshold for the convergence criterion we used the default value of the glmertree R-package, namely
abstol = 0.001.
Convergence problems of MOB-RI and metaMOB are due to fitting linear mixed-effects regression models
(M1,M2 or M3) in each iteration step . The lme4 R-package reports two different convergence warnings for
MOB-RI, metaMOB-RI and metaMOB-SI. The most frequent of the convergence warnings, more than 80%
of all the warnings in our simulations, is the warning Eager and Roy assume to be the least problematic.
Another problem for fitting the models M1, M2 and M3 in the simulation study arises due to the evaluation
of the scaled gradient. However, convergence problems were rare in the simulation study, see Table 3. The
largest number of obtained convergence warnings across the three MOB algorithms accounting for clustered
data was obtained by metaMOB-RI which uses model M2 and therefore estimates the variance component
of two random effects. In practise, researches often simplify their random effect structure in the presence
of convergence problems. If metaMOB-RI’s underlying mixed-model is the model of choice and researches
are faced with convergence problems, metaMOB-SI should be used instead. This is also recommended
by Kontopantelis (2018) for IPD meta-analysis one-stage models. Further operation characteristics as for
example the tree accuracy are based on cases without convergence warnings.
MOB-RI metaMOB-RI metaMOB-SI
Null Model (162 Settings) 0.02% 1.59% 0.07%
Sim1 (324 Setting) 0.05% 1.61% 0.07%
Sim2 (162 Settings) 0.05% 1.39% 0.06%
Table 3: Frequency of convergence problems using MOB-RI, metaMOB-RI or metaMOB-SI. For each setting
2000 simulation runs were performed.
The computation time of MOB is the smallest, since the data partition is only performed once. The mean
computation time for MOB is ∼ 2s. MOB-RI and metaMOB-RI need ∼ 5s on average for growing a tree
adjusting for between-study heterogeneity and metaMOB-SI needs ∼ 7s for growing a tree. The computation
times for all methods seem reasonable. The maximum calculation time was 215 seconds using metaMOB-RI.
3.4.2 False discovery rate
The false recovery rate is assessed by using the Null model for data generation. When the random effects
b0 or b1 are not correlated with one of the covariates the false discovery rates lie below 0.055 for all the
considered settings and methods. False discovery rates slightly larger than 0.05 are mainly observable for
settings including 2000 observations in total. Benefits of using methods accounting for the between trial
heterogeneity as MOB-RI, metaMOB-RI and metaMOB-SI are observable in the false discovery rates for
settings in which the random effects b0 or b1 are correlated with one of the splitting candidates. Figure
2 shows, that MOB’s false discovery rate increases with increasing variance of the random intercept τ20 ,
whereas MOB-RI, metaMOB-RI and metaMOB-SI’s false discovery rates are smaller when no treatment
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Figure 2: False discovery rate in setting with b0 correlated with one of the covariates but b1 uncorrelated.
Dotted line at value 0.05 indicates the pre-specified level of significance used as stopping criteria in the
algorithm. Rows represents the variance of the random treatment effect and columns represent sample sizes
and number of trials.
heterogeneity between studies is present. When the variance of both random intercept and random slope are
unequal to zero resulting in M2 being the true underlying model, the use of MOB-RI results in higher false
discovery rates (see Figure 2) since it does not adjust for heterogeneity in the treatment effect. A correlation
of the random slope b1 with one of the covariates additionally adds to spurious detections of subgroups
using MOB-RI. This is depicted in Figure 3. metaMOB-RI’s and metaMOB-SI’s false discovery rates are
not strongly influenced by the presence of random effects or a correlation of random effects with a splitting
candidate. For the two variations of metaMOB we mainly observe false discovery rates close to 0.05.
3.4.3 Tree accuracy
In settings using Sim A as data generating model, the accuracy of MOB-RI and MOB deteriorates with
increasing heterogeneity in the treatment effect if the heterogeneity of the treatment effect is correlated with
one of the splitting candidates (see Figure 4). The accuracy of the trees obtained by MOB or MOB-RI is
slightly larger in settings in which the treatment heterogeneity is correlated with X1, X2 or X5, one of the
subgroup-defining covariates, compared to settings in which the treatment heterogeneity is correlated with
a non-splitting variable. Without b1 and X being correlated (see first column of Figure 4), no difference
between the four methods with regard to tree accuracies is observable. For uncorrelated b1 and X, but
X and b0 correlated, accuracies much smaller than one are only observable for for MOB. MOB-RI adjusts
for between trial heterogeneity in baseline characteristics using a random intercept. Therefore, smaller
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Figure 3: False discovery rate for settings with b1 correlated with one of the covariates but b0 uncorrelated.
Dotted line at value 0.05 indicates the pre-specified level of significance used as stopping criteria in the
algorithm.
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Figure 4: Tree accuracy for Sim A (M2 as data-generating mechanism) with b0 and the covariates X are
uncorrelated. The correlation of b1 and the covariates X is varied (columns). Different variances of the
random intercept are presented in the three rows of the figure.
accuracies for MOB-RI are only observable in settings with τ21 6= 0 and X and b0 correlated (results not
shown). The deterioration of the accuracy with increasing variance of the treatment heterogeneity using
MOB and MOB-RI is mainly due to estimated trees with too many splits. It seems that MOB and MOB-RI,
which do not adjust for heterogeneity in the treatment effect, try to capture this heterogeneity which is linked
to covariates by further splitting the data. However, the additional splits are not necessarily performed on
covariates correlated to the between-trial heterogeneity.
Using M3 as data generating model as is Sim B, we observe that metaMOB-SI which is using the correct
model identifies trees closest to the true underlying tree (see Figure 5). However, in settings without between-
trial heterogeneity in the treatment effect or without correlation of the random treatment effect and one of
the potential splitting covariates, the mean accuracies of MOB, MOB-RI and metaMOB-RI are not much
smaller than the tree accuracy of metaMOB-SI. Larger variations in trial and subgroup specific intercepts
as the presence of between-trial heterogeneity in the treatment effect result in smaller tree accuracies of
MOB, MOB-RI and metaMOB-RI due to their model misspecification. Although metaMOB-RI accounts for
heterogeneity in both, the baseline and the treatment effect, the assumption for the baseline is not flexible
enough for this setting. The underlying model of metaMOB-RI assumes that the between-trail heterogeneity
of the baseline effects is the same across all subgroups, which is not the case in Sim B.
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Figure 5: Tree accuracy for Sim B (M3 as data-generating mechanism). The correlation of b1 and the
covariates X is varied (columns). Different variances for the subgroup and trial specific intercepts are
presented in the three rows.
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Figure 6: Correlation of true and estimated treatment effect identified subgroups in Sim A. Figure includes
only settings in which b0 and the covariates are not correlated.
3.4.4 Correlation of the estimated and true individual treatment effect
For the correlation of the estimated and true individual treatment effect the treatment effects are calculated
on a test sample. For this calculation, the patients of the test data are assigned to a subgroup according to
the grown tree. Based on this subgroup assignment model M0 to model M3 are fitted. The model is chosen
according to the MOB algorithm used for growing the tree. The true treatment effect in the estimated
subgroups is calculated by a weighted mean of the true treatment effect θ. The weights are based on the
number correctly assigned patients to each of the true subgroups. Simulations runs which failed to grow
a tree, runs with convergence problems of M1 to M3 on the test data and runs in which not all identified
subgroups are present in the test data are omitted for the calculation of the mean correlations of the settings
presented in Figure 6.
Figure 6 shows that MOB and MOB-RI’s correlation of true and estimated treatment effect decreases
when random effects are misspecified by MOB’s underlying model. This is the case in settings with τ21 6= 0 for
both MOB and MOB-RI and in setting with τ20 6= 0 for MOB only. For both metaMOB-RI and metaMOB-
SI, which have more general models underlying the tree algorithm, correlations close to 1 are observable
throughout the considered settings shown in Figure 6. The results presented in Figure 6 consider a larger
absolute treatment effect difference, e.g. standardized treatment effects |θ1/σ| = |θ3/σ| = 1 with σ = 5.
As the probability of identifying the correct treatment-by subgroup interaction decreases with decreasing
treatment-by subgroup interaction effects (Alemayehu et al., 2018; Huber et al., 2019), we can also expect
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smaller correlations of true and estimated treatment effects in the identified subgroups similar to the results
in Fokkema et al. (2018).
4 Discussion
We proposed metaMOB, a tree based method, allowing to identify treatment-by subgroup interactions while
accounting for between-trial heterogeneity in IPD- meta-analysis settings. The method metaMOB falls into
the broad class of GLMM-trees introduced by Fokkema et al. (2018). GLMM-trees allow to estimate random
effect parameters and to apply recursive partitioning to the data as proposed by Zeileis et al. (2008). The
approach used in the algorithm for GLMM-trees was also adapted in PALM-trees Seibold et al. (2018) which
allows to estimate further fixed effects which are constant over all groups instead of random effects. GLMM-
trees were only investigated for a simpler mixed model, namely a random intercept model, underlying the
partitioning. We referred to the investigated GLMM-tree as MOB-RI, model-based recursive partitioning
with a random intercept. In a simulation study, we evaluated the performance of MOB, MOB-RI and meta-
MOB in IPD meta-analysis settings with continuous response. We considered two variations of metaMOB,
namely metaMOB-RI and metaMOB-SI. Both methods model between-trial variations of the treatment ef-
fect using random effects as commonly done in random-effects meta-analysis. However, metaMOB-RI and
metaMOB-SI differ in their assumptions regarding the baseline effects. One of the models assumes the
between-trial heterogeneity in the baseline effect to be fixed. Therefore, the method uses a stratified inter-
cept approach (metaMOB-SI), whereas the other model assumes the heterogeneity in the baseline effect to
be random as well (metaMOB-RI). The simulation study showed that all four considered methods perform
similarly well in terms of false discovery rate and identifying correct subgroups, when no between-trial hetero-
geneity is present or when between-trial heterogeneity is independent from potential splitting candidates and
can therefore not be explained by any of the covariates. However, in IPD meta-analysis settings we believe
it is reasonable to assume that heterogeneity between trials is linked to one or more covariates. For those
settings, the simulation study showed that misspecifying the structure of the between-trial heterogeneity
results in less accurate trees and high false discovery rates. The misspecified between-trial heterogeneity also
affects the estimated treatment effects in the identified subgroups. The correlation of the estimated and true
treatment effect in the identified subgroups decreases when we model the data with simpler models compared
to the more complex true model. As assumptions regarding treatment effect heterogeneity between trials and
a correlation between heterogeneity and covariates seem reasonable in IPD meta-analysis, we can conclude
that MOB and the MOB-RI are not the best option for subgroup identification in IPD meta-analysis set-
tings. The method metaMOB-SI showed the best performance with regard to false discovery rate, accuracy
of identified subgroups and estimated treatment effect throughout all considered simulation settings. Com-
pared to metaMOB-RI, metaMOB with stratified intercepts has also less convergence problems as only one
random effect has to be estimated. Commonly, one of the main interest in random-effects meta analysis is
obtaining an unbiased summarized treatment effect based on several studies by accounting for between-trial
heterogeneity, which is done by both metaMOB-RI and metaMOB-SI. However, metaMOB-SI’s underly-
ing model does not impose a constraint on the baseline effects as it is done by metaMOB-RI’s underlying
model. Therefore, metaMOB-SI is more flexible. It has to be kept in mind, however, that the number of
parameters which have to be estimated for metaMOB-SI increases with increasing number of trials and also
with increasing number of identified subgroups. This might lead to inconsistent estimators as described by
the Neyman-Scott problem (Neyman and Scott, 1948). Therefore, the number of subgroups which can be
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identified by metaMOB-SI is strongly restricted for meta-analysis with smaller sample sizes and numerous
included studies.
One limitation of our simulation study is that we assumed larger number of trials as motivated by the exam-
ples (presented in the Introduction). Turner et al. (2012) found that 50% of 14886 aggregated meta-analyses
included in their analysis were based on 3 trials or less. Only 25% of the analysed meta-analysis included
6 or more studies. For IPD meta-analysis it might be even harder to retrieve data from a larger number of
trials. First, larger number of trials have to be eligible for the IPD meta-analysis and second all authors have
to agree sharing their data. Contacting and communicating with all authors is time-consuming and might
often not be successful due to problems in communication and in data-sharing agreements. Furthermore,
the anonymisation of raw data might often be challenging especially in the case of studies with numerous
covariates. Although there is an increasing interest in improving reproducible research and therefore making
raw data available for further research in practise major hurdles have to be overcome.
Difficulties in estimating the between-trial variance may arise, when data from few trials are analysed. Es-
pecially higher fractions of estimates of the between-trial heterogeneity in the treatment effect (τ1) equal to
zero in meta-analyses with few trials (Friede et al., 2017) may negatively affect subgroup identification using
MOB-RI or metaMOB. Further research on the performance of metaMOB for IPD-meta-analysis settings
with few trials is needed.
Although we considered continuous outcomes only in our simulation study, the proposed approach is appli-
cable more widely including binary endpoints, since the implementation by Fokkema et al. (2018) is based
on generalized mixed effect models. Therefore, metaMOB might also be applicable to discretely measured
time-to-event outcomes as the log-likelihood of a discrete time-to-event model and a regression model for a
binary outcome are equivalent (Schmid et al., 2016). However, the assessment of the properties of metaMOB
with discrete time-to-event endpoints is subject to future research.
SIDES for IPD meta-analysis (Mistry et al., 2018) is similar to MOB-RI regarding the assumptions of the
between-trial heterogeneity. Both account for between-trtial heterogeneity in the baseline only. Both, SIDES
for IPD meta-analysis and the GLMM-tree framework, however, do not account for between-trial heterogene-
ity in the treatment effect within identified subgroups. It is assumed that the between-trial heterogeneity
accounted for by random effects is constant across identified subgroups. As between-trial variations of the
treatment-by subgroup interactions are reasonable assumptions research for identifying subgroups in such
settings using tree-based methods is needed.
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